Patent ID: 7282351

Claim:
An isolated nucleic acid molecule selected from the group consisting of: I. a first polynucleotide which hybridizes under stringent conditions to the complement of a second polynucleotide, wherein the first polynucleotide encodes a polypeptide which is capable of stimulating the proliferation of human endothelial cells in the presence of the comitogen ConA, and the second polynucleotide is selected from the group consisting of: (a) a polynucleotide encoding amino acid residues 1 to 295 of SEQ ID NO:2; (b) a polynucleotide encoding amino acid residues 2 to 295 of SEQ ID NO:2; (c) a polynucleotide encoding amino acid residues 16 to 295 of SEQ ID NO:2; (d) a polynucleotide encoding the amino acid sequence of a full-length prostatic growth factor (PGF) polypeptide having the amino acid sequence encoded by the coding sequence of the human PGF cDNA contained in ATCC Deposit No. 75902; (e) a polynucleotide encoding the amino acid sequence of a full-length (PGF) polypeptide, excluding the N-terminal methionine, having the amino acid sequence encoded by the coding sequence of the human PGF cDNA contained in ATCC Deposit No. 75902; (f) a polynucleotide encoding the amino acid sequence of the mature (PGF) polypeptide having the amino acid sequence encoded by the coding sequence of the human PGF cDNA of the clone deposited as ATCC Deposit No. 75902; and (g) a polynucleotide which hybridizes under stringent conditions to the full complement of the polynucleotide set forth in SEQ ID NO:1; II. a polynucleotide selected from the group consisting of: (h) a polynucleotide fragment of SEQ ID NO:1 comprising at least 30 contiguous nucleotides of SEQ ID NO:1; and (i) a polynucleotide fragment of SEQ ID NO:1 comprising at least 50 contiguous nucleotides of SEQ ID NO:1; and III. a polynucleotide fully complementary to the polynucleotide of (a), (b), (c), (d), (e), (f), (g), (h), or (i).